Skip to content

Study · Measured the body's own peptide · 1983

1 result

Pure RBC aplasia and myasthenia gravis. Coexistence of two diseases associated with thymoma.

Socinski MA, Ershler WB, Frankel JP, Albertini RJ, Ciongoli AK, Krawitt EL, Burns SL, Mangan KF

Archives of internal medicine1 Mar 1983Cited by 8 (Europe PMC)

PMID6338853 (opens in a new tab)DOI10.1001/archinte.1983.00350030157027 (opens in a new tab)PepBankPUB-06338853
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Natural levels measured1

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelCase report or seriesOther

    A patient with pure RBC aplasia and myasthenia gravis had elevated circulating levels of the body's own thymosin alpha‑1.

    In plain wordsOne patient with pure red cell aplasia and myasthenia gravis had raised levels of the body's own thymosin alpha‑1 in the blood.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseCirculating thymosin alpha 1 in a patient with PRCA and MG
    Study

    n = 1

    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    We describe a patient in whom PRCA and MG occurred in conjunction with the presence of serum autoantibodies, evidence for a serum inhibitor of erythropoiesis, and elevation of circulating thymosin alpha 1.

    This result measures the body's own Thymosin alpha-1. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.